Our website uses essential cookies and, with your consent, additional cookies to measure performance and improve our services. Cookie Policy.
You can change your choice at any time.
Tag
This study reveals that over one-third of patients with localized PDAC receiving neoadjuvant therapy and surgery achieve actual five-year survival, highlighting the impact of early systemic failure and identifying factors predicting long-te
In elderly patients with locally advanced esophageal squamous cell carcinoma, neoadjuvant immunochemoradiotherapy offers superior tumor response but increases surgical complexity and cardiac risks compared to immunochemotherapy. Personalize
This review synthesizes evidence from a phase 3 trial demonstrating improved pathological complete response rates with neoadjuvant anbenitamab and HB1801 in ERBB2-positive breast cancer, highlighting efficacy, safety, and clinical implicati
Neoadjuvant chemoimmunotherapy significantly improves pathologic response rates in resectable head and neck squamous cell carcinoma compared to immunotherapy alone, potentially transforming preoperative treatment strategies.
Neoadjuvant chemoimmunotherapy significantly improves pathologic complete and major responses compared to immunotherapy alone in resectable head and neck squamous cell carcinoma, suggesting a promising avenue to improve treatment outcomes.
Updated PIVOTAL Phase III trial data demonstrate that neoadjuvant intralesional Daromun significantly improves recurrence-free and distant metastasis-free survival in resectable stage III melanoma without new safety concerns at 36.8 months
A multi-institutional study of 483 patients shows that combining macroscopic (TBSr) and histologic (TRG) response to neoadjuvant therapy better stratifies recurrence risk after hepatectomy for colorectal liver metastases than either measure alone.
The DAPHNe trial demonstrates excellent 5-year outcomes for stage II–III ERBB2-positive breast cancer patients treated with an abbreviated neoadjuvant paclitaxel, trastuzumab, and pertuzumab regimen, with ultrasensitive ctDNA monitoring sho
This review evaluates the prognostic value of Major Pathologic Response (MPR) in pancreatic ductal adenocarcinoma, analyzing its impact on survival and its potential to guide personalized adjuvant treatment strategies.
This exploratory analysis of the Phase III JCOG1109 trial suggests that postoperative complications do not significantly impair long-term survival in patients receiving intensive neoadjuvant therapy for esophageal cancer, particularly when
The Phase 3 CASSANDRA trial reveals that the four-drug PAXG regimen significantly improves event-free survival compared to mFOLFIRINOX in patients with resectable or borderline resectable pancreatic ductal adenocarcinoma, potentially redefi
A Phase II trial demonstrates that combining lenvatinib with pembrolizumab prior to surgery in Merkel cell carcinoma results in a 57.7% pathological complete response rate, suggesting a highly effective new strategy for managing resectable
The ALTER-L043 trial reveals that combining penpulimab, anlotinib, and chemotherapy achieves a staggering 76% major pathologic response rate in resectable non-small cell lung cancer, signaling a potential shift in neoadjuvant treatment para
The 5-year update of the CinClare trial demonstrates that adding irinotecan to neoadjuvant chemoradiotherapy, guided by UGT1A1 genotype, significantly improves long-term survival and disease-free outcomes in patients with locally advanced r
A Phase II trial demonstrates that the THAG regimen—combining immunotherapy, radiotherapy, and chemotherapy—significantly improves R0 resection rates and survival in patients with BRPC and LAPC, supported by IL-6 and ctDNA biomarker insight
The CARABELA trial suggests that while neoadjuvant abemaciclib plus letrozole did not meet the threshold for similarity to chemotherapy in highly proliferative HR+/HER2- breast cancer, it remains a viable alternative for patients with lower
This Phase II trial demonstrates that combining nivolumab with carboplatin and paclitaxel as neoadjuvant therapy for SCCHN achieves a 45% pathologic complete response rate and high 3-year survival, offering a promising strategy for locally
The PLANeT trial demonstrates that low-dose pembrolizumab (50 mg) plus chemotherapy significantly improves pathological complete response rates in triple-negative breast cancer, offering a high-efficacy, cost-effective alternative for resou
A phase 2 trial reports notable pCR rates and manageable toxicity for Disitamab Vedotin plus gemcitabine in HER2-positive MIBC patients.
A randomized phase II trial of the bispecific HER2-directed ADC TQB2102 (n=104) showed robust total pathologic complete response rates (tpCR 57.7–76.9% across cohorts) with manageable grade ≥3 toxicity and no treatment‑related deaths, suppo